Adverse-Effect Profile of Kava
- 1 October 2001
- journal article
- research article
- Published by Cambridge University Press (CUP) in CNS Spectrums
- Vol. 6 (10) , 848-853
- https://doi.org/10.1017/s109285290000167x
Abstract
The use of alternative therapies has increased substantially over the last decade, particularly for more chronic conditions such as anxiety. Among the most widely used treatments are medicinal herbs, or phytomedicines, such as kava (Piper methysticum), which has demonstrated anxiolytic activity in both animal models and clinical samples. Kava has several advantages over conventional pharmacologic treatments for anxiety—in clinical settings it has been associated with better tolerability and lack of physiologic dependence and withdrawal. However, phytomedicines are not rigorously regulated in the United States and systematically collected safety data are very limited. These issues are a leading concern regarding the safety of medicinal herbs such as kava. In this report, the safety profile for kava is provided, including findings from a study of its use in generalized anxiety disorder. Safety parameters assessed include occurrence of adverse events, withdrawal symptoms, effect on heart rate, blood pressure, laboratory assessments, and sexual function. No differences were found between kava and placebo on any of the parameters evaluated. The data support the safety of kava in treating anxiety at 280 mg kava lactones/day for 4 weeks.Keywords
This publication has 26 references indexed in Scilit:
- Nekrotisierende Hepatitis nach Einnahme pflanzlicher HeilmittelDeutsche Medizinische Wochenschrift (1946), 1998
- [3H]-Monoamine Uptake Inhibition Properties of Kava PyronesPlanta Medica, 1997
- Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performanceDrug and Alcohol Review, 1997
- Kava-kava Extract WS 1490 versus Placebo in Anxiety Disorders - A Randomized Placebo-controlled 25-week Outpatient TrialPharmacopsychiatry, 1997
- Kava and dopamine antagonism.Journal of Neurology, Neurosurgery & Psychiatry, 1995
- A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Ipsapirone Versus Lorazepam in Patients With Generalized Anxiety DisorderJournal of Clinical Psychopharmacology, 1993
- DEVELOPMENT OF TOLERANCE TO KAVA IN MICEClinical and Experimental Pharmacology and Physiology, 1991
- POSITIVE INTERACTION OF ETHANOL AND KAVA RESIN IN MICEClinical and Experimental Pharmacology and Physiology, 1990
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959